Imlifidase

Name: Imlifidase in Kidney transplantation in highly sensitized patients: Access and distribution
Published: 2026-09-14T15:39:06-04:00

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Access and distribution

2 evidence topics · 2 sources

Hospital restriction

“Imlifidase is restricted to hospital use only.” (opens the source at this quote in a new tab)

European and MENA rights acquired by SERB

“completed the acquisition of exclusive development and commercialization rights to Idefirix® (imlifidase)” (opens the source at this quote in a new tab)